Teva Pharmaceuticals News
The latest news, announcements and press releases from Teva Pharmaceuticals.
Wondering how Teva found room to cut $3B? Look at its past mistakes, CEO says
SAN FRANCISCO—Since new CEO Kåre Schultz rolled out Teva’s $3 billion cost-cutting plan a few weeks back, “some have asked me, ‘how on earth is this possible?’” he said Monday at the J.P. Morgan Healthcare Conference.
Read the full story »
Generic drugs giant Teva to cut workforce by more than 25%
No decision on future of Irish plants which employ about 580
Read the full story »
Teva shares up on report of 10,000 job cuts
Generic pharma company employs some 500 in Ireland
Read the full story »
Teva betting on Schultz as CEO with $40m package
Dane lands top job with beleaguered generics giant after reviving Lundbeck’s fortunes
Read the full story »
Teva sees higher active pharmaceutical ingredient sales in 2016
Copaxone maker Teva Pharmaceutical Industries Ltd. saw higher active pharmaceutical ingredient (API) sales last year.
in-2016
Read the full story »
Drug firm Teva predicts 2017 revenue and profit below estimates
Israel company expects earnings per share of $4.90-$5.30 on revenue of $23.8bn-$24.5bn
Read the full story »
Teva Reports First Quarter 2016 Results
Teva Reports Second Quarter 2016 Results
Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) today reported results for the quarter ended June 30, 2016.
Read the full story »
Teva completes acquisition of Allergan’s generic’s business
Deal was announced a year ago and came with $40.5bn price tag
Read the full story »
Takeda and Teva Establish “Teva Takeda Yakuhin Ltd.” in Japan
Takeda and Teva Establish “Teva Takeda Yakuhin Ltd.” in Japan
Read the full story »
Israel's Teva to buy Allergan for $40.5bn
Israeli pharmaceutical giant Teva said that it was buying the generic drug business of Allergan for $40.5 billion, consolidating its position as a world leader in generics.
Read the full story »
Unsolicited Takeover Bid for Mylan
Teva, the world’s biggest maker of generic medicines, offered $82 a share in cash and stock, according to a statement. That’s about 23 percent above Mylan’s closing price April 16, the day before Bloomberg News reported Teva was considering a bid. Mylan, which says it makes about one of every 11 drugs prescribed to Americans, has said it wants to stay independent and that a combination with Teva would face antitrust hurdles.
Read the full story »
Teva to buy U.S. drug developer Auspex Pharma for $3.5 billion
Israel's Teva Pharmaceutical Industries said it would buy U.S. neurology drug company Auspex Pharmaceuticals Inc for an equity value of $3.5 billion to boost its portfolio of treatments for the central nervous system.
Read the full story »
Claim This Profile
This is the News section of the company profile page for
Teva Pharmaceuticals on the
Pharmaceutical Services Directory. Companies listed on the directory can update their business
information free of charge. If this is your company and you'd like to claim this profile, please
Contact Us.
Teva Pharmaceuticals company details, activities,
contacts and reviews.
Teva Pharmaceuticals latest news, announcements and
press releases.
Teva Pharmaceuticals legal and financial information.
Teva Pharmaceuticals documents, images and videos.
Teva Pharmaceuticals global factories, offices and
locations.
Teva Pharmaceuticals blogs, articles and journal
posts.
Teva Pharmaceuticals partnership and licensing
opportunities.
